Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Abdominal Pain
9%
Adulthood
9%
Agalsidase-β
100%
Antibody Titer
9%
Arteriopathy
9%
Capillary Endothelium
27%
Cellular Injury
9%
Classic Phenotype
9%
Clinical Manifestations
9%
Early Onset
9%
Enzyme Replacement Therapy
18%
Evidence Support
9%
Fabry
45%
Fabry Disease
100%
Foot Length
9%
GL(3)
100%
GLA Gene
9%
Globotriaosylceramide
9%
Kidney Biopsy
9%
Low-dose Regimen
9%
Lysosomal Storage Disease
9%
Major Organs
9%
Male Patients
9%
Multisystem
9%
Organ Complications
18%
Organ Involvement
9%
Pathological Histology
9%
Pediatric
27%
Pediatric Patients
100%
Podocyte
9%
Randomized Controlled Trial
100%
Renal Function
9%
Symptomatology
9%
Three-level
27%
Treatment Effect
9%
Vascular Injury
9%
Vital Organs
9%
X-linked
9%
β-Galactosidase (β-Gal)
9%
Medicine and Dentistry
Abdominal Pain
14%
Agalsidase Beta
100%
Artery Disease
14%
Blood Vessel Injury
14%
Capillary Endothelium
42%
Cell Damage
14%
Drug Dose Regimen
14%
Enzyme Replacement Therapy
28%
Fabry Disease
100%
Galactosidase
14%
Globotriaosylceramide
14%
Kidney Function
14%
Low Drug Dose
100%
Lysosomal Storage Disease
14%
Pediatrics
42%
Pediatrics Patient
100%
Physical Disease by Body Function
14%
Podocyte
14%
Primary Outcome
14%
Randomized Controlled Trial
100%
Renal Biopsy
14%
Skin Capillary
42%
Storage Disease
14%
Symptomatology
14%
Treatment Effect
14%
Biochemistry, Genetics and Molecular Biology
Blood Plasma
100%
Drug Dose Regimen
33%
Enzyme
66%
Fabry Disease
100%
Galactosidase
33%
Globotriaosylceramide
33%
Kidney Function
33%
Low Drug Dose
100%
Podocyte
33%
Randomized Controlled Trial
100%
Titer
33%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Pain
14%
Agalsidase Beta
100%
Artery Disease
14%
Blood Vessel Injury
14%
Fabry Disease
100%
Galactosidase
14%
Globotriaosylceramide
14%
Lysosome Storage Disease
14%
Physical Disease by Body Function
14%
Randomized Controlled Trial
100%
Replacement Therapy
28%
Storage Disease
14%
Symptomatology
14%